LONGBIO-B(01779),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01779 LONGBIO-B

Market Closed 08-07 16:08:11

113.000

+5.900

+5.51%

High118.000	Low108.600	Vol88.95K
Open109.000	D1 Closing107.100	Amplitude8.78%
Mkt Cap8.62B	Tradable Cap8.48B	Total Shares76.32M
T/O10.03M	T/O Rate0.12%	Tradable Shares75.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"LONGBIO-B","latestPrice":113,"timestamp":1786090091888,"preClose":107.1,"halted":0,"volume":88950,"delay":0,"changeRate":0.05508870214752573,"floatShares":75059200,"shares":76322100,"eps":-3.605924384713735,"marketStatus":"Market Closed","change":5.9,"latestTime":"08-07 16:08:11","open":109,"high":118,"low":108.6,"amount":10033497,"amplitude":0.087768,"askPrice":113,"askSize":50,"bidPrice":112.6,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-2.962832657447426,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":7,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":107.1,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":1.1936777356733217,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01779","defaultTab":"news","newsList":[{"id":"1157958258","title":"LONGBIO-B Proposes Implementation of H Share Option and Incentive Schemes","url":"https://stock-news.laohu8.com/highlight/detail?id=1157958258","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157958258?lang=en_us&edition=fundamental","pubTime":"2026-07-16 06:50","pubTimestamp":1784155827,"startTime":"0","endTime":"0","summary":"The board of LONGBIO-B (01779) has resolved to propose the adoption of an H share option scheme and an H share incentive scheme for the company.The proposed schemes aim to establish and improve the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651499707","title":"Longbio Pharma Proposes H-share Option, Incentive Plans with 10% Scheme Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2651499707","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651499707?lang=en_us&edition=fundamental","pubTime":"2026-07-16 06:08","pubTimestamp":1784153288,"startTime":"0","endTime":"0","summary":"LongBio Pharma proposes H-share option, incentive plans with 10% scheme capLongBio Pharma (Suzhou) proposed adopting an H Share Option Scheme, an H Share Incentive Scheme.Equity awards could be settle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL8vC8WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108444695","title":"LONGBIO-B: FDA Clears LP-003 Clinical Trial Application for Peanut Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1108444695","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108444695?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:21","pubTimestamp":1783902099,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug application for LP-003 to treat peanut allergy. Food...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138810338","title":"FDA Grants Approval for LONGBIO-B's LP-003 Clinical Trial Application Targeting Peanut Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1138810338","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138810338?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:18","pubTimestamp":1783901912,"startTime":"0","endTime":"0","summary":"LONGBIO-B has announced that its clinical trial application for LP-003 targeting the peanut allergy indication has received approval from the U.S. Food and Drug Administration (FDA).Food allergies,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","01779","LABU","IBBQ","BK1161","BK4588","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651116145","title":"Longbio Pharma Says FDA Clears Lp-003 Peanut Allergy Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2651116145","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651116145?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:09","pubTimestamp":1783901388,"startTime":"0","endTime":"0","summary":"LongBio Pharma says FDA clears LP-003 peanut allergy clinical trial applicationLongBio Pharma (Suzhou) won US FDA clearance for its clinical trial application for LP-003 in peanut allergy.LP-003 is an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL9VKZnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651316148","title":"Longbio Pharma (suzhou) Co - FDA Approves Clinical Trial Application for Lp-3 for Peanut Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651316148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651316148?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:09","pubTimestamp":1783901375,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43C16N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130187592","title":"LongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1130187592","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130187592?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:24","pubTimestamp":1783337071,"startTime":"0","endTime":"0","summary":"LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133494330","title":"LONGBIO-B Issues 2.12895 Million Shares Following Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1133494330","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133494330?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:22","pubTimestamp":1783336935,"startTime":"0","endTime":"0","summary":"LONGBIO-B (01779) has announced the issuance and allotment of 2.12895 million H shares.This share issuance is a result of the full exercise of an over-allotment option, which was completed on July 6, 2026.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196851211","title":"LongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1196851211","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196851211?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:07","pubTimestamp":1783336036,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189095400","title":"LongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06","url":"https://stock-news.laohu8.com/highlight/detail?id=1189095400","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189095400?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:45","pubTimestamp":1782989108,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176724510","title":"Longbio-B Concludes Share Price Stabilization Period and Related Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=1176724510","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176724510?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:44","pubTimestamp":1782989079,"startTime":"0","endTime":"0","summary":"Longbio-B (SEHK: 01779) has announced the conclusion of the share price stabilization period for its global offering.The stabilization period ended on Thursday, July 2, 2026, which marks 30 days...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648501661","title":"Longbio Pharma Says IPO Stabilization Period Ends After Full 2,128,950-share Greenshoe Exercise at HK$ 96.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2648501661","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648501661?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:40","pubTimestamp":1782988842,"startTime":"0","endTime":"0","summary":"LongBio Pharma says IPO stabilization period ends after full 2,128,950-share greenshoe exercise at HK$ 96.06LongBio Pharma’s IPO stabilization period ended July 2, 2026, 30 days after the Hong Kong pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL7Nbn8H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648591623","title":"LongBio Pharma Nets HK$194 Million From Full Exercise of Hong Kong IPO Overallotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2648591623","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648591623?lang=en_us&edition=fundamental","pubTime":"2026-07-01 11:06","pubTimestamp":1782875180,"startTime":"0","endTime":"0","summary":"LongBio Pharma   said the overallotment option of its Hong Kong initial public offering was fully exercised on Tuesday, according to a same-day Hong Kong bourse filing.The biopharmaceutical company expects to receive additional net proceeds of about HK$194.3 million.The exercise involved the issue of 2.13 million additional H-shares at HK$96.06 each, representing about 15% of the total offer shares available under the global offering.Dealings in the overallotment shares are expected to begin on July 6, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01779","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173293167","title":"LongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1173293167","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173293167?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:44","pubTimestamp":1782830681,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126218520","title":"LongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1126218520","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126218520?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:42","pubTimestamp":1782830577,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123698768","title":"LONGBIO-B Fully Exercises Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1123698768","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123698768?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:32","pubTimestamp":1782829939,"startTime":"0","endTime":"0","summary":"The company has announced that the sole sponsor and overall coordinator, acting on behalf of the international underwriters, has fully exercised the over-allotment option as detailed in the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130468719","title":"Longbio-B Surges Over 6% as Phase III Trial for Seasonal Allergic Rhinitis Hits Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1130468719","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130468719?lang=en_us&edition=fundamental","pubTime":"2026-06-30 11:08","pubTimestamp":1782788904,"startTime":"0","endTime":"0","summary":"Shares of LONGBIO-B (01779) have risen more than 6%. At the time of writing, the stock is up 6.56% to HK$161, with a trading turnover of HK$22.92 million.The move follows a recent company...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","III","01779","BK1161","BK4585","VXUS","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642265502","title":"LongBio Pharma (Suzhou) (SEHK:1779) Stock Valuation Looks Stretched After Recent Gain And High P/B Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2642265502","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642265502?lang=en_us&edition=fundamental","pubTime":"2026-06-12 13:25","pubTimestamp":1781241940,"startTime":"0","endTime":"0","summary":"Event overview and immediate market reaction\nLongBio Pharma (Suzhou) (SEHK:1779) moved higher in the latest session, with the stock closing at HK$141.9 after a 3.2% gain for the day, drawing fresh attention from biotech focused investors.\nSee our latest analysis for LongBio Pharma (Suzhou).\nThe 3.2% one day share price return fits into a year to date share price return of 7.66%. This suggests momentum has been gradually building as investors reassess LongBio Pharma (Suzhou)'s risk and growth...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1779/longbio-pharma-suzhou-shares/news/longbio-pharma-suzhou-sehk1779-stock-valuation-looks-stretch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1779/longbio-pharma-suzhou-shares/news/longbio-pharma-suzhou-sehk1779-stock-valuation-looks-stretch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256141","title":"LongBio Pharma's Seasonal Allergy Drug LP-003 Meets Main Goal of Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256141","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256141?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:40","pubTimestamp":1781232040,"startTime":"0","endTime":"0","summary":"LongBio Pharma's  seasonal allergic rhinitis treatment LP-003 met the main goal of a phase 3 study, the firm said in a Hong Kong bourse filing Friday.According to LongBio, the late-stage study in China met its pre-specified primary endpoints with \"highly statistically and clinically significant\" results.The firm enrolled 546 patients in the study, including those who did not achieve satisfactory results with standard treatment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118631830","title":"LongBio Pharma’s LP-003 Hits Primary Goals in China Phase III Seasonal Allergic Rhinitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1118631830","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118631830?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:20","pubTimestamp":1781216447,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. reported that its lead candidate LP-003 met all pre-specified primary endpoints in a China-based Phase III clinical trial targeting moderate-to-severe seasonal...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longbio.com","stockEarnings":[{"period":"1week","weight":0.1728},{"period":"1month","weight":0.1888},{"period":"3month","weight":0.1763},{"period":"ytd","weight":0.1763}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":0.0607},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0336},{"period":"1year","weight":0.0234},{"period":"ytd","weight":0.0015}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"LongBio Pharma (Suzhou) Co Ltd is a China-based company primarily engaged in the in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. The Company's research and development platforms mainly include High-Affinity Antibody Discovery Platform and Bi-functional Antibody Development Platform. The Company's drug treatment direction mainly includes seasonal allergic rhinitis (AR), chronic spontaneous urticaria (CSU), allergic asthma, food allergy and other allergic diseases, also paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated kidney diseases, which includes IgA nephropathy (IgAN), C3 glomerulopathy (C3G) and lupus nephritis (LN) and other complement related indications. The Company mainly operates its businesses in the domestic market.","exchange":"SEHK","name":"LONGBIO-B","nameEN":"LONGBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LONGBIO-B(01779),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LONGBIO-B(01779) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LONGBIO-B,01779,LONGBIO-B股票,LONGBIO-B股票老虎,LONGBIO-B股票老虎国际,LONGBIO-B行情,LONGBIO-B股票行情,LONGBIO-B股价,LONGBIO-B股市,LONGBIO-B股票价格,LONGBIO-B股票交易,LONGBIO-B股票购买,LONGBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LONGBIO-B(01779),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LONGBIO-B(01779) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}